ArticleCase reports in women's health2026
Corded and hyalinized endometrioid carcinoma: A case report.
Article in Case reports in women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corded and hyalinized endometrioid carcinoma (CHEC) is a rare histologic variant of endometrioid adenocarcinoma first described in 2005. Due to its biphasic appearance, comprising traditional low-grade endometrioid carcinoma and corded/spindled cells within a hyalinized stroma, CHEC may be misdiagnosed as more aggressive malignancies, including uterine carcinosarcoma. Here is presented the case of an 84-year-old woman who was initially diagnosed with uterine carcinosarcoma but was ultimately found to have FIGO Grade 2 Stage IA2 endometrioid adenocarcinoma with CHEC features following multi-institutional pathologic review. Histopathologic and molecular characterization, including wild-type p53 staining, nuclear β-catenin expression, and a CTNNB1 exon 3 mutation, facilitated the amended diagnosis. Given the updated diagnosis, adjuvant treatment was de-escalated to vaginal brachytherapy alone, sparing the patient unnecessary systemic chemotherapy. This case underscores the critical role of molecular and immunohistochemical analysis in differentiating CHEC from more aggressive endometrial cancers, thus preventing overtreatment. Increased awareness and documentation of CHEC are essential to refining diagnostic criteria, informing prognosis, and optimizing patient management. Future studies are needed to further characterize the molecular landscape and clinical behavior of this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.